Implantable CGM tied to ‘effective’ glycemic control in diabetes

Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% and similar glycemic outcomes in the second half of the year compared with the first half, according to a presenter.
As Healio previously reported in September 2024, the FDA granted clearance to the Eversense 365 (Senseonics), a CGM sensor that is placed under the skin and has a lifespan of 1 year. The device was cleared for adults aged at least 18 years with type 1 or type 2 diabetes. In findings presented at the International Conference on Advanced Technologies &




